Search
Lecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Categories: P-glycoprotein substratesMethacetin methoxy-C-13
go.drugbank.com/drugs/DB15885InvestigationalSynonyms: p-Acetanisidine C-13Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalThe ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].
Bicyclol
go.drugbank.com/drugs/DB16014InvestigationalBicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLuvadaxistat
go.drugbank.com/drugs/DB16067InvestigationalLuvadaxistat is under investigation in clinical trial NCT03214588 (Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia).
Categories: D-Amino Acid Oxidase InhibitorORP-101
go.drugbank.com/drugs/DB16072InvestigationalORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesMiricorilant
go.drugbank.com/drugs/DB16234InvestigationalMiricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking An...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsBeta-(1,3)-D glucan
go.drugbank.com/drugs/DB16468InvestigationalSynonyms: PC-3 type glucan, Poly(1-3)-beta-D-glucan